Prudential plc’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.77M Sell
35,365
-7,635
-18% -$521K 0.02% 361
2026
Q1
$2.78M Sell
43,000
-27,250
-39% -$1.92M 0.02% 351
2025
Q4
$4.73M Buy
70,250
+31,077
+79% +$2.09M 0.04% 294
2025
Q3
$2.87M Sell
39,173
-3,645
-9% -$242K 0.02% 348
2025
Q2
$2.23M Sell
42,818
-27,431
-39% -$1.56M 0.01% 397
2025
Q1
$4.48M Buy
70,249
+12,174
+21% +$707K 0.02% 288
2024
Q4
$2.78M Buy
58,075
+1,813
+3% +$93K 0.01% 332
2024
Q3
$3.22M Buy
56,262
+14,344
+34% +$822K 0.02% 328
2024
Q2
$2.19M Hold
41,918
0.01% 378
2024
Q1
$1.71M Buy
41,918
+8,145
+24% +$305K 0.01% 426
2023
Q4
$1.25M Buy
+33,773
New +$1.27M 0.01% 515

Other funds holding HALO

Prudential plc's HALO Position: Q2 2026 in Review

Prudential plc reduced its Halozyme (HALO) stake by 18% in Q2 2026, selling an estimated $521K and leaving 35,365 shares worth $2.77M. The position accounts for 0.02% of the portfolio, ranked #361.

Prudential plc first reported a position in HALO in Q4 2023 and has held it in 11 quarters since. The position peaked at $4.73M in Q4 2025. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Prudential plc held 35,365 shares of Halozyme worth $2.77M as of Q2 2026.
  • Prudential plc sold 7,635 Halozyme shares in Q2 2026, an estimated $521K.
  • Halozyme made up 0.02% of Prudential plc's portfolio in Q2 2026, its #361 holding.
  • Prudential plc first reported a position in Halozyme in Q4 2023 and has held it in 11 quarters since.
  • Prudential plc's Halozyme position peaked at $4.73M in Q4 2025.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Prudential plc's 13F filing for Q2 2026, filed 14 Aug 2026.